

**Olga Marchenko, MS**  
**Director, Biostatistics Consulting, Oncology, i3 Statprobe**  
**Head of Adaptive Design Consulting Group**

As Director, Biostatistics Consulting, Olga Marchenko is responsible for providing strategic leadership for the design and analysis of clinical trials, senior biostatistical oversight on projects, and biostatistical consulting services to clients. She serves as a resource for the department to provide integrity in the application of statistical methodology to clinical trials in a regulated environment. As head of the Adaptive Design Consulting Group, Olga is responsible for managing the group, keeping up with industry and academic research in the area, providing consultation and support to clients and statisticians working on trials utilizing adaptive design methodology, and providing training to the department in the area of adaptive designs and sequential methods.

Prior to joining i3, Olga Marchenko worked at the Ann Arbor, Michigan office of Pfizer. Prior to Pfizer, Olga was part of the biostatistical consulting department at Statprobe, Inc., where she provided full statistical support for over 100 clinical trials, five oncology programs, two cardiovascular programs, and several global regulatory submissions.

Olga received her master's degree in science mathematics from the Belarusian State University in Minsk (Belarus) and her master's degree in statistics from the Ohio State University in Columbus, Ohio. Currently, Olga is working on her PhD thesis in statistics at the University of Michigan, Ann Arbor. Olga made presentations on adaptive designs in clinical trials at several conferences in US, Europe, and Asia during the last couple of years. This summer, she presented a talk titled "Adaptive Designs in Dose Ranging Studies" at the 1st International Symposium on Biopharmaceutical Statistics in Shanghai, China.

**Lance Teschmacher, PhD**  
**Manager, Biostatistics, i3 Statprobe**  
**Member of Adaptive Design Consulting Group**

As a manager of biostatistics, Lance is responsible for directing and coordinating biostatistical activities and operations, and has worked on a number of customer alliance projects in Phase I – Phase IV studies. He served on a Data Safety Monitoring Board for an oncology product and has most recently been involved in early phase oncology studies.

Lance has been a member of the Adaptive Design Consulting Group since its inception. His focus is on dose-response adaptive design methods. Prior to joining i3, Lance worked for two years at Pfizer, where he focused on Phase II CNS compounds.

Lance received a BA in Applied Mathematics and Management Science from the University of California, San Diego, an MS in Statistics from San Diego State University, and a Ph.D. in Applied Statistics from the University of California, Riverside.